-
Oct 04 |
Diagnostics World | It is no surprise that clinical trial sponsors are slowly embracing new tools and technologies to achieve greater levels of precision and efficiency needed in an increasingly demanding and competitive drug discovery and development landscape. Where there was once hesitation due to the unknowns of straying from historical analytic processes, there has been exponential growth in the application of digital pathology within clinical research and development efforts in recent years.
More
-
Oct 03 |
Diagnostics World | Proscia yesterday launched Concentriq Embeddings for whole slide images and the Proscia AI Toolkit, a collection of tutorials and functions to help teams rapidly integrate Concentriq Embeddings into their workflows.
More
-
Oct 01 |
Diagnostics World | In a first for genetic diagnostics, a pair of Nobel-Prize-winning technologies are being repurposed for obtaining RNA from disease-causing genes that are expressed in neither blood nor skin. The feat comes from the Neurobiology Research Group at the University of Adelaide’s School of Biomedicine, led by Lachlan Jolly, Ph.D., which aims to resolve the pathogenicity of 300 variants of uncertain significance (VUSs) under a government-funded, Australia-wide study.
More
-
Sep 26 |
Diagnostics World | Inflammatix plans to get its lead product, the TriVerity Acute Infection and Sepsis Test (TriVerity), out to market; Syantra aims to commercialize its first test on its patent-pending platform for early detection of breast cancer; and more.
More
-
Sep 25 |
Diagnostics World | QIAGEN has entered a collaboration with Eli Lilly to support the development of a QIAstat-Dx in-vitro diagnostic (IVD) to detect APOE genotypes; Illumina welcomed the European Court of Justice's judgment ruling that the European Commission did not have jurisdiction over Illumina's acquisition of GRAIL; Ambry Genetics announced enhancements to their portfolio of tests for the detection of genetic mutations associated with hereditary cancer; and more.
More
-
Sep 19 |
Diagnostics World | Researchers at the Mayo Clinic have developed a new tool that uses machine learning to analyze a stool sample to provide insights into your gut health. The tool, called the Gut Microbiome Wellness Index 2 (GMWI2), can detect subtle changes in the gut to see if one is progressing toward better health or possibly developing a disease.
More
-
Sep 18 |
Diagnostics World | The push in personalized medicine to look beyond the genome has netted quite a few valuable ‘omics technologies. Linus Bio is tracking environmental exposures recorded over time in hair. Manish Arora, CEO and founder of LinusBio, believes the platform will “revolutionize personalized medicine.”
More
-
Sep 17 |
Diagnostics World | Daye, a women's health startup, is addressing the gender diagnostic gap with a novel self-sampling tampon that collects vaginal and cervical fluids for STI and HPV testing. Lindus Health collaborated with Daye to enroll 250 diverse participants and run the STAMP trial evaluating the efficacy of the diagnostic tampon for STIs and bacterial vaginosis (BV).
More
-
Sep 12 |
Diagnostics World | Multi-cancer early detection (MCED) technology is going to be the best way to achieve population-scale cancer control, and Grail hopes its Galleri blood test that screens for more than 50 types of cancer is among the first to be approved by the U.S. Food and Drug Administration (FDA).
More
-
Sep 10 |
Diagnostics World | A team of Iraqi and Australian researchers from Middle Technical University (MTU) in Baghdad, Iraq, and the University of South Australia (UniSA) collaborated to develop an AI model that can predict diseases based on the color of the patient’s tongue.
More
-
Oct 02 |
CovarsaDx, a prominent Clinical Research Organization (CRO) renowned for its expertise in vitro diagnostics (IVDs) and medical devices, is proud to announce its membership in the Medical Device Innovation Consortium (MDIC). This partnership marks a significant milestone in CovarsaDx’s ongoing mission to advance innovation in healthcare technology by providing reliable clinical validation results from an elite network of experienced investigators.
More
-
Sep 25 |
Duke Street Bio Ltd has announced that the European Medicines Agency (EMA) has granted approval to commence a clinical trial for its highly-selective PARP1 inhibitor, DSB2455.
More
-
Sep 19 |
Medix Biochemica has announced DevCo has completed a capital raise resulting in 616 MEUR of total commitments for its long-term single asset investment vehicle for Medix Biochemica.
More
-
Sep 17 |
MX3's new Heat Stress Management Toolkit helps organizations combat heat-related stress with real-time monitoring and risk mitigation.
More
-
Sep 16 |
eClinical Solutions LLC, a global provider of digital clinical software and services, today announced that GI Partners, a private investment firm, has made a majority investment in the company to advance the future of digital trials via continued enhancements to its leading AI-powered data products and biometrics services.
More
-
Sep 11 |
PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced the launch of MET Predict† on the AISightⓇ† Image management system (IMS). MET Predict is an AI-powered algorithm designed to help pathologists identify non-small cell lung cancer (NSCLC) tumors that may be more likely to have MET exon 14 skipping (METex14) or MET amplification, directly from an H&E whole slide image.
More
-
Sep 11 |
The Verisense Smart Watch, Which Collects Digital Health Data During Clinical Trials, is Now Compatible with Both Apple and Android Smartphones.
More
-
Sep 10 |
Fimlab Laboratories, Finland’s largest provider of laboratory services, research, and training, is taking the next step on its digital pathology journey with Proscia®, a global leader in AI-enabled pathology solutions for precision medicine. The company will use Proscia’s software platform to help its pathologists generate more precise results with artificial intelligence (AI).
More
-
Sep 10 |
Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, will participate in the “This or That? Debating the Role of Panels, Exomes, and Genomes in the Diagnostic Odyssey” Educational Breakout Session (EBS), and will present two posters at the upcoming National Society for Genetic Counselors’ (NSGC) 2024 Annual Meeting taking place September 17 – 21, 2024 at the New Orleans Ernest N. Morial Convention Center in New Orleans, LA. Baylor Genetics will also be exhibiting in booth 427.
More
-
Sep 06 |
Proscia and Smart Reporting have partnered to help pathologists inform treatment decisions.
More
View more articles